(2026). Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR‐Mutated Advanced NSCLC: The Impact of Post‐Progression Management. Thoracic Cancer.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR‐Mutated Advanced NSCLC: The Impact of Post‐Progression Management."
Thoracic Cancer 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR‐Mutated Advanced NSCLC: The Impact of Post‐Progression Management."
Thoracic Cancer, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.